Integra LifeSciences (IART) Tops Q4 EPS by 1c; Offers 2022 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts IART Hot Sheet
Join SI Premium – FREE
Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.84, $0.01 better than the analyst estimate of $0.83. Revenue for the quarter came in at $405.5 million versus the consensus estimate of $403.4 million.
GUIDANCE:
Integra LifeSciences sees FY2022 EPS of $3.27-$3.35, versus the consensus of $3.42. Integra LifeSciences sees FY2022 revenue of $1.58-1.6 billion, versus the consensus of $1.63 billion.
For earnings history and earnings-related data on Integra LifeSciences (IART) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- FVCBankcorp, Inc. (FVCB) Misses Q3 EPS by 2c
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
